D016499ProceduresE02.095.465.425.750E02.186.750E02.815.520110.99903Radioimmunotherapyprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonWake Forest School of Medicine27893434McGinnis GJ, Friedman D, Young KH, Torres ER, Thomas CR, Gough MJ, Raber JOncotargetMcGinnis GJ, Friedman D, Young KH, Torres ER, Thomas CR, Gough MJ, Raber J. Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model. Oncotarget. 2017 Feb 07; 8(6):9155-9173.Oncotarget2017-02-07T00:00:002017Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model.16193312Persson M, Tolmachev V, Andersson K, Gedda L, Sandström M, Carlsson JEuropean journal of nuclear medicine and molecular imagingPersson M, Tolmachev V, Andersson K, Gedda L, Sandström M, Carlsson J. [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging. 2005 Dec; 32(12):1457-62.Eur J Nucl Med Mol Imaging2005-09-29T00:00:002005[(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.Internal Medicine, Hematology & OncologyStevenParkSteven Park MD3224Park, StevenClinical Professor32658627Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, Rimsza LM, Smith SM, Miller TP, Friedberg JWJournal of clinical oncology : official journal of the American Society of Clinical OncologyPersky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, Rimsza LM, Smith SM, Miller TP, Friedberg JW. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol. 2020 Sep 10; 38(26):3003-3011.J Clin Oncol2020-07-13T00:00:002020Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.true1Clinical ProfessorClinical Professor20345222Li L, Quang TS, Gracely EJ, Kim JH, Emrich JG, Yaeger TE, Jenrette JM, Cohen SC, Black P, Brady LWJournal of neurosurgeryLi L, Quang TS, Gracely EJ, Kim JH, Emrich JG, Yaeger TE, Jenrette JM, Cohen SC, Black P, Brady LW. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg. 2010 Aug; 113(2):192-8.J Neurosurg2010-08-01T00:00:002010A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.20935465Nguyen V, Conyers JM, Mintz ACancer biology & therapyNguyen V, Conyers JM, Mintz A. Pretargeting the masses: a means of improving and mainstreaming targeted molecular delivery? . 2010 Oct 15; 10(8):775-9.2010-10-15T00:00:002010Pretargeting the masses: a means of improving and mainstreaming targeted molecular delivery?0.1941930.1941931research area of0.7775250.06974575subject area for